Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Geneva, Switzerland and Boston, MA - January 5, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in JP Morgan's 36th Annual Healthcare Conference being held from January 8-11, 2018 in San Francisco.
ObsEva's presentation will take place on Thursday, January 11 at 8 a.m. Pacific Time (PT). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
CEO Office contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c5d0fcf7-167f-4b83-b660-893da2f380b1
